| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/21/2014 | US8632763 Use of a copolymer in the form of a solubiliser for a poorly water-soluble compound |
| 01/21/2014 | US8632753 Multivalent constructs for therapeutic and diagnostic applications |
| 01/21/2014 | US8632751 Scanning suspension comprising a particle with a diameter of at least 1 micrometer |
| 01/21/2014 | US8632565 Bonding tissues and cross-linking proteins with naphthalimide compounds |
| 01/21/2014 | CA2745782C Pharmaceutical compositions and uses for peptide treatment |
| 01/21/2014 | CA2745034C Ceramic honeycomb structure skin coating |
| 01/21/2014 | CA2734284C Pyrazolone derivative formulations |
| 01/21/2014 | CA2698396C Interferon alpha2a modified by polyethylene glycol, the preparation and use thereof |
| 01/21/2014 | CA2671000C Method for suppressing coloring of adhesive preparation containing donepezil and method for reducing amounts of donepezil-related substances formed |
| 01/21/2014 | CA2631123C Composition in the form of a spray containing a corticoid and an oil phase |
| 01/21/2014 | CA2617147C Formulation of radioprotective .alpha.,.beta. unsaturated aryl sulfones |
| 01/21/2014 | CA2613208C N, n-bis- (2-hydroxyethyl) glycine amide as linker in polymer conjugated prodrugs |
| 01/21/2014 | CA2595115C Fusion proteins for treating, preventing or ameliorating pain |
| 01/21/2014 | CA2545066C A reagent system and method for modifying the luminescence of lanthanide(iii) macrocyclic complexes |
| 01/21/2014 | CA2486473C Vaginal care composition |
| 01/21/2014 | CA2388477C Recombinant gelatins with uniform molecular weight |
| 01/21/2014 | CA2359317C Method of treating restenosis by antisense targeting of c-myc |
| 01/16/2014 | WO2014012090A1 Molecular sleds comprising a positively-charged amino acid sequence and a molecular cargo and uses thereof |
| 01/16/2014 | WO2014012063A1 Pharmaceutical dosage forms comprising ecopipam free base or pharmaceutically acceptable salts thereof |
| 01/16/2014 | WO2014011875A1 Pharmaceutical compositions for topical delivery of photosensitizers and uses thereof |
| 01/16/2014 | WO2014011813A1 Compositions containing hc-ha/ptx3 complexes and methods of use thereof |
| 01/16/2014 | WO2014011705A1 Vault immunotherapy |
| 01/16/2014 | WO2014011672A1 Etanercept formulations exhibiting marked reduction in sub-visible particles |
| 01/16/2014 | WO2014011629A1 Stable aqueous formulations of etanercept |
| 01/16/2014 | WO2014011521A1 Immunoconjugates comprising anti - cd79b antibodies |
| 01/16/2014 | WO2014011520A1 Immunoconjugates comprising anti-cd22 antibodies |
| 01/16/2014 | WO2014011519A1 Immunoconjugates comprising anti-cd79b antibodies |
| 01/16/2014 | WO2014011518A1 Immunoconjugates comprising anti-cd22 antibodies |
| 01/16/2014 | WO2014011489A2 Monoclonal antibodies for use in diagnosis and therapy of cancers and automimmune disease |
| 01/16/2014 | WO2014010586A1 Pharmaceutical preparation for injection |
| 01/16/2014 | WO2014010577A1 Aqueous pectin solution |
| 01/16/2014 | WO2014010528A1 Oxaliplatin-containing pharmaceutical composition |
| 01/16/2014 | WO2014010244A1 Food composition with improved flavor persistence |
| 01/16/2014 | WO2014010008A1 Capsule-filling composition of candesartan cilexetil |
| 01/16/2014 | WO2014009930A1 Use of nanodiamonds for generating free radicals for therapeutic purposes under radiation |
| 01/16/2014 | WO2014009805A1 Liquid compositions comprising iron for use in the treatment of disorders or diseases related to an iron deficiency |
| 01/16/2014 | WO2014009774A1 Conjugates of cell binding molecules with cytotoxic agents |
| 01/16/2014 | WO2014009500A1 Anti-tumoral composition comprising the compound 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea |
| 01/16/2014 | WO2014009437A1 Oxidation stability of abiraterone acetate |
| 01/16/2014 | WO2014009434A1 Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate |
| 01/16/2014 | WO2014009429A1 Anandamide-modified nucleic acid molecules |
| 01/16/2014 | WO2014009328A1 A method to produce a medicinal product comprising a biologically active protein and the resulting product |
| 01/16/2014 | WO2014009241A1 Diclofenac formulations |
| 01/16/2014 | WO2014008612A1 Method for inducing immune tolerance using non-proliferative polymer-modified allogeneic leukocytes |
| 01/16/2014 | WO2014008611A1 Method for inducing immune stimulation using non-proliferative allogeneic leukocytes |
| 01/16/2014 | WO2014008610A1 Acellular pro-tolerogenic compositions for treatment/prevention of graft rejection |
| 01/16/2014 | WO2014008609A1 Acellular pro-tolerogenic compositions for the treatment/prevention of auto-immune diseases |
| 01/16/2014 | WO2014008608A1 Acellular pro-tolerogenic compositions and process for making same |
| 01/16/2014 | WO2013177187A3 Synergistic tumor treatment with extended-pk il-2 and therapeutic agents |
| 01/16/2014 | WO2013156488A3 Optimised subcutaneous therapeutic agents |
| 01/16/2014 | US20140018442 Novel stabilized carotenoid compositions |
| 01/16/2014 | US20140018440 Medical devices having polymer brushes |
| 01/16/2014 | US20140018435 Transdermal Delivery of Therapeutic Agents Using Poly (Amidoamine) Dendrimers |
| 01/16/2014 | US20140018425 Controlled release formulations of levodopa and uses thereof |
| 01/16/2014 | US20140018404 Controlled release oral dosage forms of poorly soluble drugs and uses thereof |
| 01/16/2014 | US20140018397 Sustained Release Aminopyridine Composition |
| 01/16/2014 | US20140018395 Controlled Release Auris Sensory Cell Modulator Compositions and Methods for the Treatment of Otic Disorders |
| 01/16/2014 | US20140018392 Solid dosage formulations of narcotic drugs having improved buccal adsorption |
| 01/16/2014 | US20140018369 Controlled release sterile injectable aripiprazole formulation and method |
| 01/16/2014 | US20140018346 Pharmaceutical composition comprising a poorly water-soluble active ingredient, a surfactant and a water-soluble polymer |
| 01/16/2014 | US20140018328 Clear, Greaseless Skin Care Compositions |
| 01/16/2014 | US20140018323 Sustained-release injectable formulation |
| 01/16/2014 | US20140018298 Citrate free pharmaceutical compositions comprising anakinra |
| 01/16/2014 | US20140017331 Polysaccharide-containing block copolymer particles and uses thereof |
| 01/16/2014 | US20140017329 Nanoformulation and methods of use of thyroid receptor beta1 agonists for liver targeting |
| 01/16/2014 | US20140017326 Novel polysaccharide derivatives and dosage forms |
| 01/16/2014 | US20140017323 Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| 01/16/2014 | US20140017322 Supramolecular functionalization of graphitic nanoparticles for drug delivery |
| 01/16/2014 | US20140017318 Method to produce a medicinal product comprising a biologically active protein and the resulting product |
| 01/16/2014 | US20140017316 Methods and compositions for treating recurrent cancer |
| 01/16/2014 | US20140017315 Methods and compositions for treeating proliferative diseases |
| 01/16/2014 | US20140017314 Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
| 01/16/2014 | US20140017305 Encapsulated liver cell composition |
| 01/16/2014 | US20140017304 Method for encapsulated therapeutic products and uses thereof |
| 01/16/2014 | US20140017300 Delivery of nucleic acid-like compounds |
| 01/16/2014 | US20140017294 Infused Carbohydrate Based Gel Pad for Sustained Oral Transmucosal Delivery |
| 01/16/2014 | US20140017285 Adjuvant nanoemulsions with phospholipids |
| 01/16/2014 | US20140017273 Albumin-Fused Anti-Angiogenesis Peptides |
| 01/16/2014 | US20140017265 Terminally Modified Polymers and Conjugates Thereof |
| 01/16/2014 | US20140017264 Dosage and administration of bispecific scfv conjugates |
| 01/16/2014 | US20140017262 Cripto binding molecules |
| 01/16/2014 | US20140017245 Klk-13 antibody inhibitor for treating dry eye |
| 01/16/2014 | US20140017241 Non-natural ribonuclease conjugates as cytotoxic agents |
| 01/16/2014 | US20140017239 IGE CH3 Peptide Vaccine |
| 01/16/2014 | US20140017210 Methods for regulating gelation of polysaccharide solutions and uses thereof |
| 01/16/2014 | US20140017200 Modified two-component gelation systems, methods of use and methods of manufacture |
| 01/16/2014 | US20140017192 Pharmaceutical composition containing block copolymer comprising boric acid compound |
| 01/16/2014 | US20140017170 Methods and compositions for localized agent delivery |
| 01/16/2014 | US20140017169 Caged cell penetrating peptide-polymer conjugates for diagnostic and therapeutic applications |
| 01/16/2014 | US20140017167 Anti-IL1RAP Antibodies and Their Use for Treating Human |
| 01/16/2014 | US20140017165 Dna repair enzyme inhibitor nanoparticles and uses thereof |
| 01/16/2014 | CA2877985A1 Anandamide-modified nucleic acid molecules |
| 01/16/2014 | CA2874904A1 Immunoconjugates comprising anti-cd22 antibodies |
| 01/16/2014 | CA2874856A1 Immunoconjugates comprising anti-cd79b antibodies |
| 01/15/2014 | EP2684950A1 Pegylated analogue protein of canine urate oxidase, preparation method and use thereof |
| 01/15/2014 | EP2684570A1 Compositions and methods for the prevention of oxidative degradation of proteins |
| 01/15/2014 | EP2684561A1 Tablet-type composition for oral administration and method for producing same |
| 01/15/2014 | EP2684560A1 Ophthalmic solution containing hyaluronic acid or salt thereof and propylene glycol |
| 01/15/2014 | EP2683753A1 Implantable bio-resorbable polymer charged with fragile macromolecules |
| 01/15/2014 | EP2683737A1 Extracellular targeted drug conjugates |